LifeSciences BC > News > Member Announcements > Page 2

ASPECT BIOSYSTEMS PARTNERS WITH MERCK, GSK, AND MCGILL UNIVERSITY TO ENABLE DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS

June 10, 2019

ASPECT BIOSYSTEMS PARTNERS WITH MERCK, GSK, AND MCGILL UNIVERSITY TO ENABLE DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS This project will leverage Aspect Biosystems’ microfluidic 3D bioprinting platform to develop highly physiological, high-throughput tissues for the accurate and predictive screening of immuno-therapeutics targeting difficult-to-treat cancers such as triple negative breast cancer. Vancouver, BC, Canada – June 4, 2019 – … Continue reading ASPECT BIOSYSTEMS PARTNERS WITH MERCK, GSK, AND MCGILL UNIVERSITY TO ENABLE DEVELOPMENT OF IMMUNO-ONCOLOGY THERAPEUTICS

NZ Technologies announces third peer-reviewed paper on TIPSO touchless image navigation; builds evidence for a technology platform designed for the OR of the future

June 10, 2019

NZ Technologies announces third peer-reviewed paper on TIPSO touchless image navigation; builds evidence for a technology platform designed for the OR of the future Vancouver, Canada — June 4, 2019 — NZ Technologies Inc. (NZTech) is pleased to announce the publication of the third clinical review this year of its TIPSO™ technology. The paper highlights TIPSO’s … Continue reading NZ Technologies announces third peer-reviewed paper on TIPSO touchless image navigation; builds evidence for a technology platform designed for the OR of the future

Touchless image navigation facilitates decision-making in the operating room

June 10, 2019

Touchless image navigation facilitates decision-making in the operating room A recent publication confirms “the utility of touchless image navigation in the sterile field in facilitating decision-making and resource allocation during endovascular procedures.” The study, published in Minimally Invasive Therapy & Allied Technologies, provides the third clinical review of TIPSO technology (NZ Technologies), a human-computer interaction based … Continue reading Touchless image navigation facilitates decision-making in the operating room

DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting

June 3, 2019

  VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development of novel cancer therapies presented clinical updates from the Company’s ongoing first- and second-line trials in patients with MGMT-unmethylated glioblastoma multiforme (GBM) at a key opinion leader … Continue reading DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting

Molecular You Named a 2019 Gartner ‘Cool Vendor’ in Healthcare Artificial Intelligence

June 3, 2019

Vancouver, May 21, 2019:  FOR IMMEDIATE RELEASE Molecular You Named a 2019 Gartner ‘Cool Vendor’ in Healthcare Artificial Intelligence The Cool Vendor report highlights interesting, new and innovative vendors, products and services.                  Vancouver, BC, May 21, 2019 /GlobeNewswire – Molecular You, a personalized digital health company, announced today that … Continue reading Molecular You Named a 2019 Gartner ‘Cool Vendor’ in Healthcare Artificial Intelligence

DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering

June 3, 2019

June 03, 2019 VANCOUVER, British Columbia and MENLO PARK, Calif., June 3, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it entered into securities purchase agreements with certain institutional investors in connection with a registered direct … Continue reading DelMar Pharmaceuticals Announces $3.6 Million Registered Direct Offering

CDRD and NEOMED Institute Join Forces to Create a New Pan-Canadian Enterprise adMare BioInnovations

May 30, 2019
CDRD AND INSTITUTE NEO MED

Vancouver, BC and Montreal, QC – May 30, 2019: Two successful Canadian innovation organizations, CDRD, Canada’s national life sciences venture, and NEOMED Institute, a leading not-for-profit R&D organization building an innovation ecosystem in Montréal, are pleased to announce that effective today, they are bringing their respective capabilities and resources together under a new co-founded pan-Canadian … Continue reading CDRD and NEOMED Institute Join Forces to Create a New Pan-Canadian Enterprise adMare BioInnovations

DelMar Pharmaceuticals Updates Key Dates of Rights Offering

May 29, 2019

VANCOUVER, British Columbia and MENLO PARK, Calif., May 29, 2019 /PRNewswire/ — DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI) (“DelMar” or the “Company”), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today provided an update to stockholders regarding the Company’s rights offering and the key dates relative to the offering.   Stockholders or interested … Continue reading DelMar Pharmaceuticals Updates Key Dates of Rights Offering

EmeTerm and HeadaTerm are Approved by TGA Australia

May 29, 2019

EmeTerm and HeadaTerm are Approved by TGA Australia WAT Medical is a company that develops safe, effective, and user-friendly wearable medical products.  With a team of devoted staff leading in the field of medical research and development, an efficient and convenient medical service is being provided for individual customers worldwide. The mission is to supply … Continue reading EmeTerm and HeadaTerm are Approved by TGA Australia

Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress

May 22, 2019
Vitaeris Inc.

Anti-Interleukin 6 Monoclonal Antibody for Antibody-Mediated Kidney Transplant Rejection  8 Oral & Poster Presentations Vancouver, Canada, May 22, 2019 – Vitaeris Inc. (Vitaeris) today announced that eight abstracts involving or related to clazakizumab, Vitaeris’ proprietary anti-interleukin-6 humanized monoclonal antibody, have been accepted for presentation at the 2019 American Transplant Congress (ATC) taking place from June … Continue reading Vitaeris Announces Multiple Scientific Presentations Involving Clazakizumab at the 2019 American Transplant Congress